Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
Identifieur interne : 001C10 ( Main/Exploration ); précédent : 001C09; suivant : 001C11Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
Auteurs : David Devos [France] ; L. Defebvre [France] ; R. Bordet [France]Source :
- Fundamental & Clinical Pharmacology [ 0767-3981 ] ; 2010-08.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Pharmacologie.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Clinical Trials as Topic, Dopamine, Dopamine (metabolism), Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (etiology), Gait Disorders, Neurologic (metabolism), Gait Disorders, Neurologic (physiopathology), Gait disorder, Glutamate, Humans, Norepinephrine, Norepinephrine (metabolism), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Parkinson disease, Parkinson’s disease, Pedunculopontine Tegmental Nucleus (drug effects), Pedunculopontine Tegmental Nucleus (metabolism), Pedunculopontine Tegmental Nucleus (physiopathology), Pharmacology, Subthalamic Nucleus (drug effects), Subthalamic Nucleus (metabolism), Subthalamic Nucleus (physiopathology), Treatment Outcome, dopamine, gait disorders, glutamate, noradrenaline, pharmacology.
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , metabolism : Dopamine, Norepinephrine.
- chemical , pharmacology : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- complications : Parkinson Disease.
- drug effects : Pedunculopontine Tegmental Nucleus, Subthalamic Nucleus.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- etiology : Gait Disorders, Neurologic.
- metabolism : Gait Disorders, Neurologic, Parkinson Disease, Pedunculopontine Tegmental Nucleus, Subthalamic Nucleus.
- physiopathology : Gait Disorders, Neurologic, Parkinson Disease, Pedunculopontine Tegmental Nucleus, Subthalamic Nucleus.
- Clinical Trials as Topic, Humans, Treatment Outcome.
Abstract
Gait disorders form one component of the axial disorders observed in Parkinson’s disease (PD). Indeed, short steps with a forward‐leaning stance are diagnostic criteria for PD in the early stages of the condition. Gait disorders also represent a major source of therapeutic failure in the advanced stages of PD (with the appearance of freezing of gait and falls) because they do not respond optimally to the two hand late‐stage therapeutics – levodopa and electrical subthalamic nucleus (STN) stimulation. The late onset of doparesistance in these disorders may be linked to propagation of neurodegeneration to structures directly involved in gait control and to non‐dopaminergic neurotransmitter systems. The coeruleus locus (a source of noradrenaline) is rapidly and severely affected, leading to a major motor impact. The pedunculopontine nucleus (PPN) and lateral pontine tegmentum (rich in acetylcholine) are both involved in gait. Degenerative damage to the serotoninergic raphe nuclei appears to be less severe, although serotonin‐dopamine interactions are numerous and complex. Lastly, dopaminergic depletion leads to glutamatergic hyperactivity of the efferent pathways from the the STN to the PPN. However, the relationships between the various parkinsonian symptoms (and particularly gait disorders) and these pharmacological targets have yet to be fully elucidated. The goal of this review is to develop the various pathophysiological hypotheses published to date, in order to underpin and justify ongoing fundamental research and clinical trials in this disease area.
Url:
DOI: 10.1111/j.1472-8206.2009.00798.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A96
- to stream Istex, to step Curation: 001A94
- to stream Istex, to step Checkpoint: 000553
- to stream PubMed, to step Corpus: 000A69
- to stream PubMed, to step Curation: 000A29
- to stream PubMed, to step Checkpoint: 000A29
- to stream Ncbi, to step Merge: 000B24
- to stream Ncbi, to step Curation: 000B24
- to stream Ncbi, to step Checkpoint: 000B24
- to stream Main, to step Merge: 001D26
- to stream PascalFrancis, to step Corpus: 000540
- to stream PascalFrancis, to step Curation: 000E17
- to stream PascalFrancis, to step Checkpoint: 000501
- to stream Main, to step Merge: 001E88
- to stream Main, to step Curation: 001C10
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease</title>
<author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name>
</author>
<author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L." last="Defebvre">L. Defebvre</name>
</author>
<author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R." last="Bordet">R. Bordet</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E30C8267F686573C916FD9B8D19D566FFA36D320</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1111/j.1472-8206.2009.00798.x</idno>
<idno type="url">https://api.istex.fr/document/E30C8267F686573C916FD9B8D19D566FFA36D320/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001A96</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A96</idno>
<idno type="wicri:Area/Istex/Curation">001A94</idno>
<idno type="wicri:Area/Istex/Checkpoint">000553</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000553</idno>
<idno type="wicri:doubleKey">0767-3981:2010:Devos D:dopaminergic:and:non</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20163480</idno>
<idno type="wicri:Area/PubMed/Corpus">000A69</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A69</idno>
<idno type="wicri:Area/PubMed/Curation">000A29</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A29</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A29</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A29</idno>
<idno type="wicri:Area/Ncbi/Merge">000B24</idno>
<idno type="wicri:Area/Ncbi/Curation">000B24</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B24</idno>
<idno type="wicri:Area/Main/Merge">001D26</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0337905</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000540</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E17</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000501</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000501</idno>
<idno type="wicri:doubleKey">0767-3981:2010:Devos D:dopaminergic:and:non</idno>
<idno type="wicri:Area/Main/Merge">001E88</idno>
<idno type="wicri:Area/Main/Curation">001C10</idno>
<idno type="wicri:Area/Main/Exploration">001C10</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease</title>
<author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology and Movement Disorders, EA2683, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">France</country>
</affiliation>
</author>
<author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L." last="Defebvre">L. Defebvre</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology and Movement Disorders, EA2683, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R." last="Bordet">R. Bordet</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Pharmacology Medical, EA 1046, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Fundamental & Clinical Pharmacology</title>
<idno type="ISSN">0767-3981</idno>
<idno type="eISSN">1472-8206</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2010-08">2010-08</date>
<biblScope unit="volume">24</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="407">407</biblScope>
<biblScope unit="page" to="421">421</biblScope>
</imprint>
<idno type="ISSN">0767-3981</idno>
</series>
<idno type="istex">E30C8267F686573C916FD9B8D19D566FFA36D320</idno>
<idno type="DOI">10.1111/j.1472-8206.2009.00798.x</idno>
<idno type="ArticleID">FCP798</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0767-3981</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Clinical Trials as Topic</term>
<term>Dopamine</term>
<term>Dopamine (metabolism)</term>
<term>Gait Disorders, Neurologic (drug therapy)</term>
<term>Gait Disorders, Neurologic (etiology)</term>
<term>Gait Disorders, Neurologic (metabolism)</term>
<term>Gait Disorders, Neurologic (physiopathology)</term>
<term>Gait disorder</term>
<term>Glutamate</term>
<term>Humans</term>
<term>Norepinephrine</term>
<term>Norepinephrine (metabolism)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson’s disease</term>
<term>Pedunculopontine Tegmental Nucleus (drug effects)</term>
<term>Pedunculopontine Tegmental Nucleus (metabolism)</term>
<term>Pedunculopontine Tegmental Nucleus (physiopathology)</term>
<term>Pharmacology</term>
<term>Subthalamic Nucleus (drug effects)</term>
<term>Subthalamic Nucleus (metabolism)</term>
<term>Subthalamic Nucleus (physiopathology)</term>
<term>Treatment Outcome</term>
<term>dopamine</term>
<term>gait disorders</term>
<term>glutamate</term>
<term>noradrenaline</term>
<term>pharmacology</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
<term>Norepinephrine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Pedunculopontine Tegmental Nucleus</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Gait Disorders, Neurologic</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Gait Disorders, Neurologic</term>
<term>Parkinson Disease</term>
<term>Pedunculopontine Tegmental Nucleus</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Gait Disorders, Neurologic</term>
<term>Parkinson Disease</term>
<term>Pedunculopontine Tegmental Nucleus</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term>
<term>Glutamate</term>
<term>Maladie de Parkinson</term>
<term>Noradrénaline</term>
<term>Pharmacologie</term>
<term>Trouble de la marche</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Pharmacologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Gait disorders form one component of the axial disorders observed in Parkinson’s disease (PD). Indeed, short steps with a forward‐leaning stance are diagnostic criteria for PD in the early stages of the condition. Gait disorders also represent a major source of therapeutic failure in the advanced stages of PD (with the appearance of freezing of gait and falls) because they do not respond optimally to the two hand late‐stage therapeutics – levodopa and electrical subthalamic nucleus (STN) stimulation. The late onset of doparesistance in these disorders may be linked to propagation of neurodegeneration to structures directly involved in gait control and to non‐dopaminergic neurotransmitter systems. The coeruleus locus (a source of noradrenaline) is rapidly and severely affected, leading to a major motor impact. The pedunculopontine nucleus (PPN) and lateral pontine tegmentum (rich in acetylcholine) are both involved in gait. Degenerative damage to the serotoninergic raphe nuclei appears to be less severe, although serotonin‐dopamine interactions are numerous and complex. Lastly, dopaminergic depletion leads to glutamatergic hyperactivity of the efferent pathways from the the STN to the PPN. However, the relationships between the various parkinsonian symptoms (and particularly gait disorders) and these pharmacological targets have yet to be fully elucidated. The goal of this review is to develop the various pathophysiological hypotheses published to date, in order to underpin and justify ongoing fundamental research and clinical trials in this disease area.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
</region>
<settlement><li>Lille</li>
</settlement>
</list>
<tree><country name="France"><region name="Hauts-de-France"><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name>
</region>
<name sortKey="Bordet, R" sort="Bordet, R" uniqKey="Bordet R" first="R." last="Bordet">R. Bordet</name>
<name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L." last="Defebvre">L. Defebvre</name>
<name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C10 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C10 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E30C8267F686573C916FD9B8D19D566FFA36D320 |texte= Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |